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Abstract
Summary Long-term persistence with anti-osteoporosis drugs
and determinants for discontinuation among fracture patients
were examined. Persistence was 75.0 and 45.3 % after 1 and
5 years, respectively. Those aged ≥80 years were at increased
risk of early discontinuation. Within 1 year after discontinua-
tion, 24.3 % restarted therapy, yet 47.0 % persisted for 1 year.
Introduction The risk of osteoporotic fracture can effectively
be reduced with use of anti-osteoporosis drugs. However, little
is known about persistence with these drugs after fracture
where subsequent fracture risk is high. The aims were to de-
termine long-term persistence with anti-osteoporosis drugs
among fracture patients, including its determinants, and to
describe restart and subsequent persistence.
Methods A cohort study was conducted within the Dutch
PHARMO Database Network. Patients aged ≥50 years
(n=961) who received anti-osteoporosis drugs within 1 year
after fracture, but not in the preceding year, were included
(2002–2011). Persistence (defined as the proportion on treat-
ment) and the proportion restarting after discontinuation were
estimated using Kaplan-Meier analyses. Time-dependent Cox
regression was used to identify determinants of non-persistence
including age, sex, initial dosage regime, fracture type, comor-
bidities, and drug use.
Results Persistence with anti-osteoporosis drugs was 75.0 %
(95 % confidence interval (CI) 72.0–77.7) and 45.3 % (95 %
CI 40.4–50.0) after 1 and 5 years, respectively. A significant
determinant of non-persistence was age ≥80 years (reference
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50–59 years: adjusted hazard ratio [adj. HR] 1.65; 95 % CI
1.15–2.38). This effect was not constant over time (≤360 days
following initiation: adj. HR 2.07; 95 % CI 1.27–3.37;
>360 days: adj. HR 1.08; 95 % CI 0.62–1.88). Within 1 year
after discontinuation, 24.3 % (95 % CI 20.1–29.2) restarted
therapy, yet 47.0 % persisted for 1 year.
Conclusions This study identified suboptimal persistence
with anti-osteoporosis drugs among fracture patients. Major
target groups for measures aimed to improve persistence may
be those aged >80 years and those restarting therapy.
Keywords Epidemiology . Fracture prevention .
Osteoporosis . Persistence . Therapeutics
Introduction
Osteoporotic fractures are a major burden for the patient in
terms of increased morbidity, mortality, and a reduction in
quality of life [1]. Prior fractures are strong predictors of frac-
ture risk. Indeed, the fracture risk is two-fold higher following
a non-vertebral fracture and is quadrupled after a vertebral
fracture [2]. This risk is not constant over time with a five-
fold higher risk in the year after the first fracture followed by a
gradual waning off [3]. Within 5 years after the initial fracture,
up to one third of the patients will sustain a new fracture [4, 5].
Anti-osteoporosis drugs, of which bisphosphonates are the
most commonly prescribed, have shown to reduce the relative
risk of osteoporotic fractures by 20–70 % in clinical trials,
depending on the drug and fracture type [6–8]. Persistence
with therapy is an important determinant for the anti-fracture
efficacy of anti-osteoporosis drugs in clinical practice [9–12].
A meta-analysis with data of 219,676 patients indicated that
non-persistence with anti-osteoporosis drugs increased frac-
ture risk by 32 % (hazard ratio (HR) 1.32; 95 % confidence
interval (CI) 1.23–1.42) where follow-up between studies var-
ied between 40 and 159 weeks [9]. The effectiveness of oral
bisphosphonates in relation to duration of use was more spe-
cifically identified in a Dutch observational study; persistent
use of oral bisphosphonates for 1–2 and 3–4 years reduced
fracture risk by 12 and 46%, respectively, compared to <1 year
of use (OR 0.88, 95 % CI 0.66–1.18 and OR 0.54, 95 % CI
0.35–0.84, respectively) [12]. Real-world persistence with os-
teoporosis therapy is, however, poor. One-year persistence
ranged from 18 to 78 % between studies where differences
were at least partly arising from non-uniformity used for the
operational definition of persistence, including data-derived
persistence and self-report [13–20].
While previous studies have been conducted among first-
time users of anti-osteoporosis drugs, there is a lack of under-
standing on fracture history with few studies identifying
patients who had (recently) sustained an osteoporotic fracture.
As a previous fracture is one of the most important risk factors
for a subsequent fracture, it is important to investigate persis-
tence with anti-osteoporosis drugs in this patient group and to
understand its determinants. Furthermore, little is known
about restart and subsequent persistence with these drugs after
first discontinuation. Therefore, the aims of this study were (1)
to identify long-term persistence with anti-osteoporosis drugs
and its determinants in patients who had recently sustained a
major osteoporotic fracture (hip, clinical vertebrae, humerus,
forearm), (2) to determine the frequency of restarting treat-
ment among patients who discontinued use, and (3) to assess
persistence after restarting anti-osteoporosis treatment.
Methods
Data source
A cohort study was performed within the Dutch PHARMO
Database Network [PHARMO Institute for Drug Outcome
Research, www.pharmo.nl]. This data source contains
primary care data linked to outpatient pharmacy dispensing
data, hospitalizations from the Dutch Hospital Data
Foundation (DHD, www.dutchhospitaldata.nl), and death
registration data for approximately 660,000 community-
dwelling individuals in the Netherlands. Almost every indi-
vidual in the Netherlands is registered with a single commu-
nity pharmacy, which results in a high degree of completeness
with regard to dispensed drugs [21]. Drug-dispensing records
contain information concerning the dispensed drug according
to the Anatomical Therapeutic Chemical (ATC) Classification
system codes including amount, dose, dosage regime, and
date of dispensing. Primary care diagnoses are coded accord-
ing to the International Classification of Primary Care (ICPC)
coding system. Hospital records include dates of hospital ad-
mission and discharge, diagnoses, and procedures recorded
according to the International Classification of Disease, 9th
or 10th revision codes (ICD-9 or ICD-10).
Study population
All patients ≥50 years with a first record of a hip, humerus,
clinical vertebral, or forearm fracture since the start of data
collection were identified. Fractures were extracted from pri-
mary care records and hospitalization data between 1 January
2002 and 31 December 2011. In the Netherlands, drugs avail-
able for the treatment of osteoporosis include bisphosphonates
(alendronic acid, risedronic acid, etidronic acid, ibandronic
acid, zoledronic acid), selective estrogen receptor modulators
(SERMS; raloxifene, bazedoxifene), strontium ranelate,
teriparatide, and denosumab.
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Patients were included at the date of first dispensing for an
anti-osteoporosis drug in the year following the first fracture
but not in the preceding year to include incident users only.
The date of the first dispensing of an anti-osteoporosis drug
after the fracture was set as the index date. Patients who
were dispensed clodronic acid, pamidronic acid, tiludronic
acid, or risedronic acid 30 mg once daily were not included
since these drugs are not registered for osteoporosis but for
hypercalcemia during malignancy or Paget’s disease, which
may also increase fracture risk. In the Netherlands, repeated
weekly dispensing of medications is an indicator of medi-
cation delivery by a “weekbox,” suggesting that patient
persistence is monitored by a health care professional,
and thus, any discontinuation is likely not patient driv-
en. To control for physician-directed discontinuation, pa-
tients with repeated weekly (7-day) dispensing records
were excluded.
Study outcomes
The outcome of interest was persistence with any anti-
osteoporosis drug. Persistence was defined as the proportion
of patients who were on treatment since treatment initiation
[22]. Assessment of persistence was based on the calculation
of the total duration of use where switching between drugs and
dosage regimes was permitted [23]. The total duration of
use was calculated on the basis of subsequent prescriptions
for anti-osteoporosis drugs that were collected by (i.e.,
dispensed to) the patient at the community pharmacy.
For each pharmacy dispensing, the theoretical duration of
use was calculated by dividing the amount dispensed by
the prescribed dosage regime. In the event of overlap be-
tween two dispensings (i.e., a repeat dispensing within the
duration of use of a previous dispensing), the overlap days
were added to the duration of the repeat dispensing. A
gap of 90 days between the theoretical end date of a
pharmacy dispensing (defined as the date of dispensing
plus the theoretical duration of use) and the subsequent
dispensing date was allowed. A patient was therefore clas-
sified as having discontinued with anti-osteoporosis treat-
ment when either a gap of >90 days occurred between
two dispensings, or when no further dispensing was issued
and at least 90 days were available to the right censoring
date. A 90-day permissible gap is consistent with prior
literature [14, 15], and the maximum amount dispensed
is a 90 days’ supply in the Netherlands for chronic treat-
ment, which is required for osteoporosis [23, 24]. In sen-
sitivity analyses, permissible treatment gaps of 180, 270,
and 365 days were applied.
Among patients who discontinued use using a 90-day per-
missible gap, the proportion restarting therapy was identified.
Persistence with any anti-osteoporosis drug upon restart of
therapy was determined similarly as described above.
Definition of covariates
Potential determinants of non-persistence (discontinuation)
with anti-osteoporosis drugs were included in univariate and
multivariate Cox proportional hazards models. Age, drug ex-
posure, and comorbidities were included as time-dependent
covariates. Total follow-up time was divided into 30-day in-
tervals, and covariates were evaluated before each interval.
Covariates included age groups (50–59, 60–69, 70–79,
≥80 years), sex, type of fracture (hip, humerus, clinical verte-
brae, forearm fracture), dosage regime of initial anti-
osteoporosis drug (daily, weekly, or monthly), drug use in
the 6 months before (systemic glucocorticoids, antidepres-
sants, non-selective anti-inflammatory drugs [NSAIDs], opi-
oids [tramadol or stronger], calcium supplements and/or vita-
min D, and disease-modifying anti-rheumatic drugs
[DMARDs]), comorbidities included a diagnosis of demen-
tia/Alzheimer’s disease ever before, and the occurrence of
upper gastrointestinal disorders or a subsequent fracture (at
any site) in the 6 months before [13, 16, 25]. The presence
of alcoholism was also considered, expressed by diagnosis
codes for alcohol dependence and alcoholic liver diseases (al-
coholic acute hepatitis, alcoholic liver cirrhosis, alcoholic liver
damage, alcoholic fatty liver) or exposure to drugs for alcohol
abstinence (disulfiram, acamprosate, nalmefene, naltrexone).
An incident diagnosis of renal failure (diagnosis for renal fail-
ure or stage 4/5 chronic kidney disease) was assessed but
occurred too infrequent to include into the analysis (n=3).
Statistical analysis
All patients were followed from the index date until discon-
tinuation, death, migration out of the data source, or end of
study period [31 December 2011], whichever came first.
Kaplan-Meier life table analyses were used to present persis-
tence estimates (%) over time where discontinuation was the
failure event. Analyses were completed using the whole
study population and stratified by age groups and type
of index fracture. Log-rank tests were used to test for
significant differences between groups. In addition, Kaplan-
Meier life tables were applied to determine the cumulative
incidence of restarting any anti-osteoporosis drug after first
90-day discontinuation.
Determinants of non-persistence were estimated by time-
dependent Cox proportional hazards regression (PHREG pro-
cedure) by entering all covariates into the regression model.
The proportional hazards assumption was tested by including
time interaction terms into the model. In case of violation
(p value interaction <0.05), hazard ratios for the association
between that covariate and non-persistence were calculated
for two periods by restricting follow-up time to the first
12 30-day periods and the period thereafter (≤360 and
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>360 days), to present the hazard ratio for “early” and
“late” discontinuation, respectively.
All statistical analyses were performed using SAS statisti-
cal software, version 9.2 (SAS Institute, Inc., Cary, NC, USA).
Results
A total of 1081 patients were identified as incident users
of anti-osteoporosis drugs within 1 year after the first
fracture. Of these, 120 patients had repeated 7-day dis-
pensing indicating “weekbox” dispensing and were exclud-
ed. The final study cohort included 961 patients (81.3 %
female) with a mean age of 69.8 years (SD=9.6 years).
The vast majority initially received a bisphosphonate
(96.5 %), most frequently alendronic acid (67.3 %) or
risedronic acid (29.7 %). Alternatives for bisphosphonates,
such as raloxifene and strontium ranelate, were rarely dis-
pensed (Table 1). During follow-up, a total of 89 (9.3 %)
patients switched between types of anti-osteoporosis drugs,
where 67.4 % of all switches occurred between alendronic
acid and risedronic acid. Bisphosphonates were predomi-
nantly prescribed in a weekly dosage regime (94.2 %). Of
patients initiating on a daily dosage, 36.4 % switched to
another dosage regime during follow-up.
Persistence estimates for treatment with anti-osteoporosis
drugs are displayed in Fig. 1a for the total study population.
Persistence decreased from 75.0 % (95 % CI 72.0–77.7) at
1 year to 45.3 % (95 % CI 40.4–50.0) at 5 years following
initiation. The median time on treatment was 4.6 years [95 %
CI 4.1–5.0]. Increasing the gap length showed increases in
persistence (Table 2). When stratified by age groups, signifi-
cant differences in persistence were identified (p=0.003), with
those aged 80 years and older at index date having the lowest
persistence (Fig. 1b), but no significant difference was noted
between fracture types (p=0.17) (Fig. 1c). Of those aged
80 years and older, 63.9 % (95 % CI 55.8–70.9) persisted
for 1 year following treatment initiation, as compared to
82.8 % (95 % CI 75.7–88.0) of those aged 50–59 years.
Table 3 presents associations between the covariates and
non-persistence with anti-osteoporosis drugs. In a multivariate
model, age ≥80 years was identified as a significant determi-
nant of discontinuation (reference 50–59 years; adjusted [adj.]
hazard ratio [HR] 1.65; 95% CI 1.15–2.38). The effect of age,
however, was not constant over time (p value interaction
<0.05). When follow-up was restricted to the first 360 days
following initiation, persistence was significantly lower for
those ≥80years as compared to those 50–59 years (adj. HR
2.07; 95%CI 1.27–3.37), while this was not observed beyond
360 days of follow-up (adj. HR 1.08; 0.62–1.88). The associ-
ation between an initial daily versus weekly dosage regime
and non-persistence was also not constant over time
(≤360 days; adj. HR 1.49, 95 % CI 0.95–2.35, >360 days;
adj. HR 0.68; 95 % CI 0.35–1.30, p value interaction
<0.05). Sensitivity analyses with increasing gap lengths pro-
vided similar results, where age ≥80 years remained the only
Table 1 Characteristics of new anti-osteoporosis drug users who
sustained a recent fracture
Characteristics N=961
Follow-up time, mean (SD), years 3.0 (2.1)
Female sex 781 (81.3 %)
Age, mean (SD), years 69.8 (9.6)
Age categories
50–59 161 (16.8 %)
60–69 308 (32.0 %)
70–79 322 (33.5 %)
≥80 170 (17.7 %)
Type of index fracture
Hip 204 (21.2 %)
Humerus 127 (13.2 %)
Clinical vertebral 322 (33.5 %)
Forearm 308 (32.0 %)
Initial anti-osteoporosis drug
Bisphosphonate 927 (96.5 %)
Alendronic acid 624 (67.3 %)
Risedronic acid 275 (29.7 %)
Other bisphosphonatea 28 (3.0 %)
Strontium ranelate 29 (3.0 %)
Otherb 5 (0.5 %)
Dosage regime
Daily 67 (7.0 %)
Weekly 873 (90.8 %)
Monthly 21 (2.2 %)
Diseases
Upper gastrointestinal disorders 6 months before
index datec
26 (2.7 %)
Dementia/Alzheimer’s disease ever before index
datec and during follow-up
25 (2.6 %)
Alcoholism ever before index datec and during
follow-up
24 (2.5 %)
Fracture at any site during follow-up 80 (8.3 %)
Upper gastrointestinal disorders during follow-up 74 (7.7 %)
Drug use during 6 months before index datec
Systemic glucocorticoids 78 (8.1 %)
Antidepressants 92 (9.6 %)
Opioids (tramadol or stronger) 97 (10.1 %)
Non-steroidal anti-inflammatory drugs 347 (36.1 %)
Calcium-supplements and/or vitamin D 64 (6.7 %)
Disease-modifying anti-rheumatic drugs 13 (1.4 %)
a Etidronic acid, ibandronic acid
b Raloxifene
c Index date defined as date of first dispensing for any anti-osteoporosis
drug within 1 year after fracture
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significant determinant of non-persistence (see supplementary
Table S1/S2/S3).
Figure 2 shows the cumulative incidence of restarting any
anti-osteoporosis drug after first discontinuation. Of all
patients who discontinued treatment, 24.3 % (95 % CI
20.1–29.2) restarted therapy within 1 year, and this in-
creased to 40.4 % (95 % CI 32.4–49.4) within 5 years.
Patients who discontinued treatment were less likely to
stay on treatment after restart; 47.0 % (95 % CI 36.4–56.9)
persisted for 1 year. The median time on treatment was
0.92 years (95 % CI 0.61–1.47) (Fig. 3).
Discussion
In this cohort of newly treated fracture patients, persistence
with anti-osteoporosis drugs decreased from 75 % at 1 year to
45 % at 5 years following initiation. Patients aged 80 years
and older were at increased risk of early discontinuation. A
substantial proportion of patients restarted treatment following
first discontinuation; yet, 47 % persisted with treatment for
1 year following restarting therapy.
Persistence estimates were higher than expected when
compared to previously conducted studies among first-time
users who did not initiate treatment specifically after fracture.
Ameta-analysis showed a pooled persistence estimate of 50%
(95 % CI 37–63 %) for treatment lasting 7 to 12 months as
measured by treatment gaps that ranged from 30 to 120 days
[19]. They also found increased persistence among patients
allowed to switch medications (58 % [95 % CI 45–70 %) vs
46 % [95 % CI 38–55 %]). Another study that was conducted
among new users irrespectively of fracture status and that
similarly defined persistence as the present study (90-day
gap and allowed switching between drugs) found a 1-year
persistence estimate of 67 % (95 % CI 66–68), which was still
lower as compared to the current study [15]. This suggests that
the setting, where treatment was initiated after a recent
Fig. 1 Kaplan-Meier persistence curves for treatment with anti-
osteoporosis drugs after a recent fracture for a the total study
population, b stratified by age category, c stratified by type of
fracture—discontinuation was defined as a treatment gap of >90 days
and switching between anti-osteoporosis drugs or dosage regimes was
allowed when this occurred within the treatment gap
Table 2 Kaplan-Meier estimates for persistence (%) at different time
periods following initiation, by gap length
Survival time
1 year 3 years 5 years
Gap length
90 days 75.0 (72.0–77.7) 61.3 (57.6–64.8) 45.3 (40.4–50.0)
180 days 79.2 (76.3–81.7) 68.2 (64.7–71.5) 53.6 (48.6–58.4)
270 days 82.2 (79.5–84.6) 73.0 (69.6–76.1) 58.9 (53.7–63.6)
365 days 84.4 (81.9–86.6) 75.2 (71.9–78.3) 64.4 (59.5–68.9)
Patients were followed until first date of the following: discontinuation
(non-persistence), death, migration out of data source, or end of study
period
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fracture, may have influenced persistence. Indeed, studies that
included patients who visited fracture liaison services (FLSs)
showed 1-year persistence that ranged between 74 and 88 %,
which were either based on self-report [25–28] or prescription
claims [29]. These numbers may, however, have been biased
upward by selection toward more motivated patients as only
patients agreeing to participate in FLSs were included (re-
sponse rate ranged between 38 and 88 %). To the best of our
knowledge, the only previously conducted population-based
study that assessed persistence after fracture (1997–2004)
showed a 1-year persistence estimate of 80 % with alendronic
acid weekly, etidronic acid, or raloxifene [30].
In a multivariable adjusted analysis, age of 80 years and
older (reference 50–59 years) was identified as a significant
determinant of non-persistence with anti-osteoporosis drugs
early after initiation. This finding is in line with the, to the
best of our knowledge, only previous study that explored de-
terminants of non-persistence with these drugs when initiated
after recent fracture (OR 1.008; 95 % CI 1.004–1.012 per year
of age) [30]. Although older age was identified as a marker for
increased risk of early discontinuation, the underlying reasons
remain unknown and may be multifactorial, including but not
limited to the number of comorbid conditions, poly-pharmacy,
physical inability or dependency of others to take medication,
or willingness to take medication.
A weekly dosage regime has now been widely adopted in
clinical practice and has been associated with increased per-
sistence when compared to a daily regime although evidence
is conflicting for the difference in persistence between weekly
and monthly regimes [13, 17]. In the present study, we did not
find evidence that daily and monthly dosage regimes of the
initial drug were associated with increased or decreased risk of
discontinuation compared to a weekly regime, respectively.
However, switching between anti-osteoporosis drugs and dos-
age regimes was permitted and may have diluted the associa-
tion. In addition, the number of daily and monthly users was
limited (daily, 7 % of whom 3.4 % were daily bisphosphonate
users; monthly, 2.2 %). Similarly, the occurrence of upper
Table 3 Determinants of non-
persistence (>90-day gap) with
anti-osteoporosis drugs after
fracture
Cr crude,Adj adjusted,HR hazard
ratio, 95 % CI 95 % confidence
interval
a Reference group is no use within
6 months prior within that drug
category
bReference group is no occurrence
within 6 months prior (ever prior
for dementia/Alzheimer’s disease
or alcoholism) within that disease
category
Cr. HR (95 % CI) Adj. HR (95 % CI)
Gender
Male Reference Reference
Female 0.91 (0.71–1.18) 0.97 (0.74–1.26)
Age categories
50–59 years Reference Reference
60–69 years 1.05 (0.75–1.47) 1.06 (0.76–1.50)
70–79 years 1.15 (0.82–1.60) 1.13 (0.80–1.58)
≥80 years 1.70 (1.20–2.42) 1.65 (1.15–2.38)
Type of index fracture
Forearm Reference Reference
Humerus 0.92 (0.65–1.31) 0.87 (0.61–1.24)
Clinical vertebral 1.22 (0.95–1.57) 1.13 (0.87–1.47)
Hip 1.24 (0.94–1.63) 1.08 (0.81–1.44)
Dosage regime
Once daily 1.21 (0.84–1.74) 1.06 (0.73–1.54)
Once weekly Reference Reference
Once monthly 0.58 (0.24–1.40) 0.58 (0.24–1.41)
Drug usea
Systemic glucocorticoids 1.21 (0.84–1.73) 1.18 (0.82–1.70)
Antidepressants 1.12 (0.81–1.55) 1.11 (0.80–1.54)
Opioids (tramadol or stronger) 1.00 (0.65–1.53) 0.83 (0.53–1.29)
Non-steroidal anti-inflammatory drugs 1.01 (0.79–1.31) 0.98 (0.76–1.27)
Calcium supplements and/or vitamin D 0.96 (0.77–1.19) 0.94 (0.76–1.17)
Disease-modifying anti-rheumatic drugs 1.01 (0.48–2.14) 1.10 (0.52–2.34)
Disease occurrenceb
Dementia/Alzheimer’s disease 1.71 (0.94–3.11) 1.46 (0.79–2.70)
Subsequent fractures 1.70 (0.91–3.21) 1.64 (0.86–3.10)
Upper gastrointestinal disorders 1.54 (0.79–3.00) 1.40 (0.71–2.74)
Alcoholism 1.55 (0.80–3.01) 1.50 (0.76–2.96)
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gastrointestinal disorders is a frequently cited reason for dis-
continuation of bisphosphonates, but this was not confirmed
in the present study [31–33]. Again, switching between anti-
osteoporosis drugs was allowed and may explain this finding.
Furthermore, a qualitative study indicated that fear for side
effects, while they did not occur yet, was enough to discon-
tinue with treatment, which was not captured in our data [26].
Approximately 40 % of patients restarted therapy within
5 years after discontinuation, of whom the majority did so
within the first 6 months. Previous studies showed proportions
of restarting patients varying between 18 and 38 % within
6 months after first discontinuation [13, 18, 34–36]. Our find-
ing of 20 % is at the lower end of this range and is in agree-
ment with a Dutch study, where 18 % of osteoporotic patients
restarted therapy within 6 months [13]. The substantial pro-
portion of patients who restarted therapy was reflected by an
increase in persistence over time when permissible treatment
gaps became wider. The present study identified that
persistence with anti-osteoporosis therapy was poor among
restarting patients. While there is little evidence of persistence
after restarting therapy, the results of this study are similar to,
to our knowledge, the only previous study to address this
issue, which identified a median duration of persistence of
6 months following restart (>60-day gap) [18].
Strengths of this study include that persistence was deter-
mined over a long-term follow-up period and that linkage of
longitudinal data of hospitalizations, diagnoses made by gen-
eral practitioners, mortality, and drug dispensing was possible.
The majority of studies on anti-osteoporosis drug persistence
included a short 1-year follow-up with a focus on first treat-
ment discontinuation. However, determining persistence for
the initial drug or first treatment period may result in an un-
derestimation of total exposure. Indeed, this study identified
that up to a quarter of patients who discontinued therapy
returned to treatment within 1 year of discontinuation which
increased to 40 % within 5 years. Although it is encouraging
that many patients may return to therapy, extended gaps in
therapy may result in reduced effectiveness. This may, how-
ever, depend on the duration of prior exposure as limited ev-
idence shows a residual anti-fracture effect during posttreat-
ment follow-up that was inversely associated with time on
treatment and may be explained by accumulation of
bisphosphonates in the bone [37].
A limitation of this study was that persistence relied on
pharmacy dispensing data where the actual intake remained
unknown. However, several studies showed that repeated dis-
pensing records are a good indicator of consumptions [38, 39].
Second, due to the coding system within general practitioner
records, we were not able to disentangle proximal humerus
fractures from those of the distal part and shaft. Proximal
humerus fractures have been associated with osteoporotic
BMD [40, 41] and fracture risk [40], while little is known
for those of the shaft and distal part where benefits of treat-
ment with anti-osteoporosis drugs may be less clear. We be-
lieve that the impact of this is limited as proximal humerus
fractures are the dominant type of humerus fractures after the
age of 50 years [42] and the study population was highly
likely to have osteoporotic BMD since the Dutch primary care
guideline primarily focusses on DXA-diagnosed osteoporosis
when considering starting anti-osteoporosis drugs after non-
vertebral fractures. Furthermore, this study only identified old
age as a significant determinant of discontinuation and the
results of several other determinants, including dementia, ex-
posure to DMARDs, initial monthly dosage regime, and
alcohol-related diagnoses, should be interpreted with caution
due to the low numbers of patients exposed. An incident di-
agnosis of renal failure may as well be a determinant of dis-
continuation but could not be included in the analyses due to
the fact that only three patients with this determinant were
present. Another limitation was that intravenously adminis-
tered anti-osteoporosis drugs (zoledronic acid) or
Fig. 3 Kaplan-Meier persistence curve for treatment with anti-
osteoporosis drugs following restart of therapy (>90-day gap)
Fig. 2 Kaplan-Meier curve for cumulative incidence of restart with anti-
osteoporosis drugs after first discontinuation (>90-day gap)
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subcutaneous drugs (e.g., teriparatide, denosumab) prescribed
by a specialist were not (completely) captured as they are
either delivered to the patient in the hospital or frequently by
special ambulatory pharmacies. A significant underestimation
of persistence due to this limitation, however, is unlikely as
zoledronic acid was not frequently administered during the
study period [43], denosumab was introduced in the Nether-
lands in the year 2011, and teriparatide is only reimbursed
under restricted conditions.
In conclusion, results identified suboptimal persistence
among a cohort of patients with prior fracture, highlighting
the need for additional research focused on improving persis-
tence among patients at high risk for subsequent fractures,
which includes a better understanding of the underlying rea-
sons for non-persistence. The results of the present study fur-
ther add to the literature by identifying the frequency of treat-
ment re-initiation following an extended gap and the subse-
quent persistence with therapy. There are a number of oppor-
tunities for improving treatment persistence, including educa-
tional interventions targeted at physicians and/or patients as
many physicians may be unaware of, and therefore unable to
address, non-adherence [44, 45] and both physicians as
patients may be sceptical or unaware of treatment benefits,
other opportunities include telephone-based counselling
[46], pharmaceutical intervention [47, 48], or use of pa-
tient decision aids [49]; yet, few have proven effective in
clinical settings [50]. Major target groups for intervention
after a recent fracture may be those aged 80 or more years
and those restarting therapy following an extended gap.
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